Real-world Data of Paclitaxel and Ramucirumab Compared to Other Treatment Regimens in Advanced Gastric Cancer

Real-world Efficacy and Toxicity Data of the Combination of Paclitaxel and Ramucirumab Compared to Other Treatment Regimens in Patients With Advanced Gastric Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06666582

Enrollment

185

Registered

2024-10-30

Start date

2015-03-01

Completion date

2024-01-15

Last updated

2024-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer Stage IV, Ramucirumab Paclitaxel, Second-line Treatment

Brief summary

Our aim was to evaluate whether second-line treatment with paclitaxel and ramucirumab was associated with improved clinical outcomes compared to other available therapies. This study involved real-world data collection, focusing on the safety and efficacy of therapeutic combinations, administered to patients with pretreated advanced gastric cancer in the Oncology Departments affiliated with the Hellenic Cooperative Oncology Group (HeCOG).

Interventions

DRUGPaclitaxel and ramucirumab

Second-line treatment with paclitaxel/ramucirumab vs other regimens

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with unresectable or metastatic, locally advanced adenocarcinoma of the stomach, gastroesophageal junction, or distal esophagus * Treated at Departments of Medical Oncology affiliated with the Hellenic Cooperative Oncology Group (HeCOG) * Second-line treatment for advanced disease * Treatment for at least two months of second-line treatment.

Exclusion criteria

* Lack of informed consent in case the patient was alive

Design outcomes

Primary

Measure	Time frame	Description
Progression-free survival	From the initiation of second-line treatment to the date of discontinuation (due to any reason), first documented progression, death from any cause or last contact, through study completion, up to 2 years	The primary endpoint of interest was the assessment of progression-free survival (PFS1), defined as the time interval from the initiation of second-line treatment to the date of discontinuation (due to any reason), first documented progression, death from any cause or last contact, whichever occurred first.

Secondary

Measure	Time frame	Description
Overall survival	From the date of disease progression to the date of death from any cause or last contact, through study completion, up to 2 years.	overall survival (OS), defined as the time interval from the date of disease progression to the date of death from any cause or last contact.

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026